<DOC>
	<DOCNO>NCT01204697</DOCNO>
	<brief_summary>This randomized parallel group study assess efficacy safety erlotinib [ Tarceva ] , monotherapy intermittent dose docetaxel , second-line set former-smoker male patient advance metastatic squamous non-small cell lung cancer . Patients randomize receive either Tarceva ( 150 mg/day orally ) monotherapy 4 cycle docetaxel ( 75 mg/m2 intravenously every 3 week ) plus Tarceva ( 150 mg/day orally , day 2-16 cycle ) follow Tarceva monotherapy . Anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Erlotinib Tarceva Monotherapy Intermittent Dosing With Docetaxel Patients With Advanced Metastatic Non-Small Cell Lung Cancer . ( TALISMAN )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>male patient , &gt; /=18 year age former smoker ( smoked &gt; /= 100 cigarette lifetime quit &gt; 12 month enrollment ) locally advanced ( stage IIIb ) , metastatic ( stage IV ) recurrent squamous nonsmall cell lung cancer prior platinumbased therapy advance NSCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 01 uncontrolled symptomatic central nervous system ( CNS ) metastases prior therapy epidermal growth factor receptor ( EGFR ) &gt; 1 prior chemotherapy advanced/metastatic NSCLC radiotherapy &lt; 28 day prior enrollment history melanoma time , another malignancy last 5 year except carcinoma situ cervix , basal squamous cell carcinoma skin , surgically cure malignant neoplasia diseasefree interval &gt; 5 year fully treat eye inflammation infection , predispose condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>